2018.10.14 First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)
2018.09.27 I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody? Platform for Three Bispecific Antibody Programs
2018.08.10 I-Mab’s Announces China Clinical Trial Approval of Long-acting hGLP-1 To Treat Type 2 Diabetes
2018.08.09 BioWorld August 9, 2018: South Korea’s ABL Bio buys bispecific antibodies from I-Mab in $100M deal
2018.07.26 I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies